CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cambium Bio Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cambium Bio Ltd
2 Paddington Street, Paddington
Phone: +61 294998010p:+61 294998010 PYMBLE, NSW  2021  Australia Ticker: CMBCMB
Business Summary
Cambium Bio Limited, formerly Regeneus Ltd, is an Australia-based clinical-stage regenerative medicine company focusing on the development of biologics for ophthalmology and tissue repair applications. Its technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Its lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. Elate Ocular is formulated from the processing of base human platelets sourced not from patients, but generally healthier younger eligible donors at U.S. blood collection centers. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. It also manufactures and sells stem cell growth supplements, such as UltraGRO Advanced, UltraGRO Pure (xeno-free), and UltraGRO Pure GI (xeno-free, gamma irradiated).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20246/30/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Barry G.Sechos 4/29/2019 7/1/2012
Chief Executive Officer KarolisRosickas 40 11/2/2020 11/2/2020
Chief Scientific Officer, Executive Director GrahamVesey 11/10/2014 8/14/2007
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Cambium Medical Technologies LLC 1055 Brookhaven Walk NE Atlanta GA United States

Business Names
Business Name
Cambium Bio Limited
Cambium Medical Technologies LLC
CMB
CMBDA
RGS

General Information
Outstanding Shares: 3,064,369 (As of 7/4/2024)
Shareholders: 124
Stock Exchange: ASX
Fax Number: +61 294998020


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024